Table 4.

Changes in circulating markers according to the treatments

	Tamoxifen (20mg/day) (N=13)		4-OHT gel (4mg/day) (N=10)
	Mean ± SD	P*	Mean ± SD	P*	P†
IGF-1 (ng/mL)
baseline	59.0 ± 11.4		63.7 ± 8.6
post-treatment	50.3 ± 9.7		58.5 ± 6.6
Changes from baseline	−8.7 ± 8.3	0.003	−5.2 ± 9.5	0.12	0.35
SHBG (ng/mL)
baseline	98.4 ± 45.0		89.4 ± 70.2
post-treatment	143.9 ± 69.0		99.7 ± 76.0
Changes from baseline	45.5 ± 40.2	0.002	10.3 ± 74.4	0.67	0.20
%vWF
baseline	167.4 ± 89.2		179.9 ± 68.3
post-treatment	218.6 ± 134.6		177.3 ± 65.3
Changes from baseline	51.2 ± 71.0	0.02	−2.6 ± 52.3	0.88	0.06
%Factor VIII
baseline	157.1 ± 47.5		158.4 ± 23.4
post-treatment	168.7 ± 51.6		167.1 ± 24.5
Changes from baseline	11.6 ± 17.3	0.03	8.7 ± 18.5	0.17	0.70
%Factor IX
baseline	86.6 ± 8.8		86.7 ± 7.0
post-treatment	87.0 ± 12.2		81.1 ± 12.7
Changes from baseline	0.4 ± 10.2	0.89	−5.6 ± 13.6	0.22	0.24
%Total Protein S
baseline	94.3 ± 8.9		97.5 ± 7.0
post-treatment	91.6 ± 12.2		95.9 ± 9.2
Changes from baseline	−2.7 ± 9.3	0.32	−1.6 ± 6.5	0.46	0.76

Abbreviation: IGF-1 = insulin-like growth factor-1; SHBG= sex hormone-binding globulin; vWF= von Willebrand factor.

^*Paired t-test between baseline and post-treatment value within a treatment group

^†Unpaired t- test for changes from baseline between treatment groups.